The Exchange had sought clarification from Aarti Drugs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013 or as per Indian Accounting Standard The response of the Company is enclosed.
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE raised two queries on Aarti Drugs' financial results for the quarter and year ended March 31, 2025, flagging that the 'Balancing Figures Note' was missing from the submission, which is required under SEBI's format and Schedule III of the Companies Act / Indian Accounting Standards. The company responded by confirming that the Q4 figures for March 31, 2025 and March 31, 2024 are balancing figures derived between the audited full-year numbers and the published year-to-date figures up to the third quarter. This is a standard accounting practice permitted under applicable standards. The clarification has been submitted for NSE's records.
This is a routine compliance clarification on a formatting/note-disclosure issue and does not indicate any financial irregularity or regulatory penalty. Shareholders are unlikely to see any material impact on the stock from this exchange.